Debrumab — Denosumab
Denosumab is unusual in our catalogue for having two genuinely different dosing strengths tied to two distinct clinical purposes — the 60mg dose we stock treats osteoporosis, while a separate 120mg formulation (not part of this SKU) is used at higher doses to prevent skeletal complications from cancer that has spread to bone. Confirming which indication a buyer needs before quoting is essential, since ordering the wrong strength means the product won't match the intended clinical use.
- Approved indications (60mg, this SKU): Osteoporosis in postmenopausal women and in men at increased fracture risk
- Mechanism: Inhibits RANK ligand, a protein essential for the formation and activity of osteoclasts, the cells that break down bone tissue
- Dosing schedule: Administered once every 6 months via subcutaneous injection — one of the least frequent dosing schedules of any biologic in our catalogue, a genuine convenience advantage
- Buyer clarification point: Confirm intended indication (osteoporosis vs. cancer-related bone disease) before finalizing an order, as the appropriate strength differs
Key Product Facts
60 mg
Strength
1 Prefilled Syringe (S) Of 1 ml
Pack Size
Denosumab
Active Ingredient
Immunology
Category
Enquire Now for Pricing
Price
Denosumab is unusual in our catalogue for having two genuinely different dosing strengths tied to two distinct clinical purposes — the 60mg dose we stock treats osteoporosis, while a separate 120mg formulation (not part of this SKU) is used at higher doses to prevent skeletal complications from cancer that has spread to bone. Confirming which indication a buyer needs before quoting is essential, since ordering the wrong strength means the product won't match the intended clinical use.
- Approved indications (60mg, this SKU): Osteoporosis in postmenopausal women and in men at increased fracture risk
- Mechanism: Inhibits RANK ligand, a protein essential for the formation and activity of osteoclasts, the cells that break down bone tissue
- Dosing schedule: Administered once every 6 months via subcutaneous injection — one of the least frequent dosing schedules of any biologic in our catalogue, a genuine convenience advantage
- Buyer clarification point: Confirm intended indication (osteoporosis vs. cancer-related bone disease) before finalizing an order, as the appropriate strength differs
- Osteonecrosis of the jaw: A rare but serious risk — dental clearance and any necessary dental work is recommended before starting treatment
- Hypocalcemia risk: Can be severe, particularly in patients with renal impairment — calcium and vitamin D supplementation is typically recommended alongside treatment
- Pediatric use: Not approved for children
- Discontinuation caution: Stopping treatment can lead to a rebound increase in fracture risk, including multiple vertebral fractures — patients should not stop without medical guidance
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Denosumab used for?
Treats osteoporosis in postmenopausal women and men at increased fracture risk.
Get Denosumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
How often is it given?
Once every 6 months by subcutaneous injection.
What are the risks?
Rare risks include jaw osteonecrosis and severe low calcium levels, both manageable with proper monitoring.
Who supplies Denosumab from India?
WHO-GMP certified manufacturer with full export documentation.
